Evidence map›Paper›PMID 23863710›Full record

ArticleThe Journal of clinical investigation2013

Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.

Rebecca L Williams-Karnesky, Ursula S Sandau, Theresa A Lusardi, Nikki K Lytle, Joseph M Farrell, Eleanor M Pritchard, David L Kaplan, Detlev Boison

Open access · greenAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 1 synthesis or guideline pooled it, 261 citations in OpenAlex.

  1. Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.Progress in neuro-psychopharmacology & biological psychiatry · 2015
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Fumonisin BEpigenetics · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Adenosine Kinase: An Epigenetic Modulator and Drug Target.Journal of inherited metabolic disease · 2025
    Review
  18. Article
  19. Article
  20. Article

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Rebecca L Williams-KarneskyRS Dow Neurobiology Laboratories, Legacy Research Institute, Portland, Oregon 97232, USA.
Ursula S Sandau
Theresa A Lusardi
Nikki K Lytle
Joseph M Farrell
Eleanor M Pritchard
David L Kaplan
Detlev Boison
Legacy Health · USTufts University · USOHSU Knight Cancer InstituteOregon Health & Science University · US

Funding

Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
Astrocyte dysfunction in epileptogenesis: the role of adenosineR01NS061844 · NINDS · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI BOISON, DETLEV · 2009 to 2013
$1.5M
Blood genomics and proteomics of CpG-induced neuroprotection in primate stroke.F30NS070359 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI WILLIAMS, REBECCA LYNN · 2010 to 2014
$220k
NIBIB NIH HHS P41 EB002520NINDS NIH HHS F30 NS070359NINDS NIH HHS F30NS070359NINDS NIH HHS R01 NS061844NINDS NIH HHS R01-NS061844
6 · The paper itself

Abstract

Epigenetic modifications, including changes in DNA methylation, lead to altered gene expression and thus may underlie epileptogenesis via induction of permanent changes in neuronal excitability. Therapies that could inhibit or reverse these changes may be highly effective in halting disease progression. Here we identify an epigenetic function of the brain's endogenous anticonvulsant adenosine, showing that this compound induces hypomethylation of DNA via biochemical interference with the transmethylation pathway. We show that inhibition of DNA methylation inhibited epileptogenesis in multiple seizure models. Using a rat model of temporal lobe epilepsy, we identified an increase in hippocampal DNA methylation, which correlates with increased DNA methyltransferase activity, disruption of adenosine homeostasis, and spontaneous recurrent seizures. Finally, we used bioengineered silk implants to deliver a defined dose of adenosine over 10 days to the brains of epileptic rats. This transient therapeutic intervention reversed the DNA hypermethylation seen in the epileptic brain, inhibited sprouting of mossy fibers in the hippocampus, and prevented the progression of epilepsy for at least 3 months. These data demonstrate that pathological changes in DNA methylation homeostasis may underlie epileptogenesis and reversal of these epigenetic changes with adenosine augmentation therapy may halt disease progression.

Indexed as

AdenosineAdenosine KinaseAnimalsAnticonvulsantsAzacitidineBase SequenceBrainCpG IslandsDecitabineDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDrug ImplantsEpigenesis, GeneticEpilepsyMaleMiceAdenosineAdenosine KinaseAnticonvulsantsAzacitidineDecitabineDNA (Cytosine-5-)-MethyltransferasesDrug Implants

Identifiers

PMID23863710
PMCPMC3726154
OpenAlexW1982903836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.